A First Evaluation of OMNI®, A New Device for Continuous Renal Replacement Therapy

Pierre Schläpfer; Jean Daniel Durovray; Valery Plouhinec; Cristiano Chiappa; Rinaldo Bellomo; Antoine Schneider

doi:10.1159/000451053

A First Evaluation of OMNI®, A New Device for Continuous Renal Replacement Therapy

Pierre Schläpfer, Jean Daniel Durovray, Valery Plouhinec, Cristiano Chiappa, Rinaldo Bellomo, Antoine Schneider

Research output: Contribution to journal › Article › Research › peer-review

10 Citations (Scopus)

Abstract

Background: Omni® (B. Braun, Germany) is a new-generation, continuous renal replacement therapy (CRRT) machine designed to improve user interface, minimize downtime and optimize renal dose delivery. It was never tested in humans. Methods: We used Omni® to provide CRRT in 10 critically ill patients. We collected therapy data, metabolic parameters and evaluated user's satisfaction with a survey. Results: CRRT was delivered using Omni® in CVVH-heparin (6 patients) and CVVHD-citrate (4 patients) modes for a total duration of 617.7 h. No adverse event was observed. The mean filter life was 22.8 (CVVH-heparin) and 33.5 (CVVHD-citrate) h. Alarms-related downtime corresponded to 5.9% of total therapy time. Delivered renal dose was 96.6% of prescribed. Satisfactory metabolic control and fluid removal were achieved. Overall, users evaluated interface, design and usability as excellent. Conclusion: CRRT in CVVH-heparin and CVVHD-citrate modes was provided using Omni® in a safe and efficient way for 10 critically ill patients. Video Journal Club ‘Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=451053.

Original language	English
Pages (from-to)	11-17
Number of pages	7
Journal	Blood Purification
Volume	43
Issue number	1-3
DOIs	https://doi.org/10.1159/000451053
Publication status	Published - Mar 2017
Externally published	Yes

Keywords

Acute kidney injury
Blood purification
Renal dose
Renal replacement therapy

Access to Document

10.1159/000451053

Cite this

@article{53d8f240e14a41b7aeb8cf5c79cb7a2a,

title = "A First Evaluation of OMNI{\textregistered}, A New Device for Continuous Renal Replacement Therapy",

abstract = "Background: Omni{\textregistered} (B. Braun, Germany) is a new-generation, continuous renal replacement therapy (CRRT) machine designed to improve user interface, minimize downtime and optimize renal dose delivery. It was never tested in humans. Methods: We used Omni{\textregistered} to provide CRRT in 10 critically ill patients. We collected therapy data, metabolic parameters and evaluated user's satisfaction with a survey. Results: CRRT was delivered using Omni{\textregistered} in CVVH-heparin (6 patients) and CVVHD-citrate (4 patients) modes for a total duration of 617.7 h. No adverse event was observed. The mean filter life was 22.8 (CVVH-heparin) and 33.5 (CVVHD-citrate) h. Alarms-related downtime corresponded to 5.9% of total therapy time. Delivered renal dose was 96.6% of prescribed. Satisfactory metabolic control and fluid removal were achieved. Overall, users evaluated interface, design and usability as excellent. Conclusion: CRRT in CVVH-heparin and CVVHD-citrate modes was provided using Omni{\textregistered} in a safe and efficient way for 10 critically ill patients. Video Journal Club {\textquoteleft}Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=451053.",

keywords = "Acute kidney injury, Blood purification, Renal dose, Renal replacement therapy",

author = "Pierre Schl{\"a}pfer and Durovray, {Jean Daniel} and Valery Plouhinec and Cristiano Chiappa and Rinaldo Bellomo and Antoine Schneider",

year = "2017",

month = mar,

doi = "10.1159/000451053",

language = "English",

volume = "43",

pages = "11--17",

journal = "Blood Purification",

issn = "0253-5068",

publisher = "S Karger AG",

number = "1-3",

}

TY - JOUR

T1 - A First Evaluation of OMNI®, A New Device for Continuous Renal Replacement Therapy

AU - Schläpfer, Pierre

AU - Durovray, Jean Daniel

AU - Plouhinec, Valery

AU - Chiappa, Cristiano

AU - Bellomo, Rinaldo

AU - Schneider, Antoine

PY - 2017/3

Y1 - 2017/3

N2 - Background: Omni® (B. Braun, Germany) is a new-generation, continuous renal replacement therapy (CRRT) machine designed to improve user interface, minimize downtime and optimize renal dose delivery. It was never tested in humans. Methods: We used Omni® to provide CRRT in 10 critically ill patients. We collected therapy data, metabolic parameters and evaluated user's satisfaction with a survey. Results: CRRT was delivered using Omni® in CVVH-heparin (6 patients) and CVVHD-citrate (4 patients) modes for a total duration of 617.7 h. No adverse event was observed. The mean filter life was 22.8 (CVVH-heparin) and 33.5 (CVVHD-citrate) h. Alarms-related downtime corresponded to 5.9% of total therapy time. Delivered renal dose was 96.6% of prescribed. Satisfactory metabolic control and fluid removal were achieved. Overall, users evaluated interface, design and usability as excellent. Conclusion: CRRT in CVVH-heparin and CVVHD-citrate modes was provided using Omni® in a safe and efficient way for 10 critically ill patients. Video Journal Club ‘Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=451053.

AB - Background: Omni® (B. Braun, Germany) is a new-generation, continuous renal replacement therapy (CRRT) machine designed to improve user interface, minimize downtime and optimize renal dose delivery. It was never tested in humans. Methods: We used Omni® to provide CRRT in 10 critically ill patients. We collected therapy data, metabolic parameters and evaluated user's satisfaction with a survey. Results: CRRT was delivered using Omni® in CVVH-heparin (6 patients) and CVVHD-citrate (4 patients) modes for a total duration of 617.7 h. No adverse event was observed. The mean filter life was 22.8 (CVVH-heparin) and 33.5 (CVVHD-citrate) h. Alarms-related downtime corresponded to 5.9% of total therapy time. Delivered renal dose was 96.6% of prescribed. Satisfactory metabolic control and fluid removal were achieved. Overall, users evaluated interface, design and usability as excellent. Conclusion: CRRT in CVVH-heparin and CVVHD-citrate modes was provided using Omni® in a safe and efficient way for 10 critically ill patients. Video Journal Club ‘Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=451053.

KW - Acute kidney injury

KW - Blood purification

KW - Renal dose

KW - Renal replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=84995802324&partnerID=8YFLogxK

U2 - 10.1159/000451053

DO - 10.1159/000451053

M3 - Article

AN - SCOPUS:84995802324

SN - 0253-5068

VL - 43

SP - 11

EP - 17

JO - Blood Purification

JF - Blood Purification

IS - 1-3

ER -

A First Evaluation of OMNI®, A New Device for Continuous Renal Replacement Therapy

Abstract

Keywords

Access to Document

Other files and links

Cite this